Cargando…
Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain
BACKGROUND: The objective of this study was to estimate the cost-effectiveness of denosumab for fracture prevention compared with no treatment, generic bisphosphonates, and strontium ranelate in a cohort of osteoporotic postmenopausal women in Spain. METHODS: A Markov model represented the possible...
Autores principales: | Darbà, Josep, Kaskens, Lisette, Sorio Vilela, Francesc, Lothgren, Mickael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4330002/ https://www.ncbi.nlm.nih.gov/pubmed/25709480 http://dx.doi.org/10.2147/CEOR.S78349 |
Ejemplares similares
-
Cost-effectiveness of bazedoxifene versus raloxifene in the treatment of postmenopausal women in Spain
por: Darbà, Josep, et al.
Publicado: (2013) -
Relationship between patient dependence and direct medical-, social-, indirect-, and informal-care costs in Spain
por: Darbà, Josep, et al.
Publicado: (2015) -
Disability-adjusted-life-years losses in postmenopausal women with osteoporosis: a burden of illness study
por: Darbà, Josep, et al.
Publicado: (2015) -
Cost-Effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in South Korea
por: Kang, Jung-Yoon, et al.
Publicado: (2022) -
Real-world cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis in Taiwan
por: Johnson, Ben, et al.
Publicado: (2021)